FMC二季度利润好于预期但收入下滑、全年盈利指引承压

AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
Introduction & Market Context
FMC Corporation (NYSE:FMC) presented its second-quarter 2026 earnings results on July 30, 2026, revealing a company in transition as it navigates patent expiration, pricing pressure, and a strategic overhaul aimed at reducing debt and repositioning its product portfolio. The agricultural sciences company reported adjusted earnings that exceeded Wall Street expectations despite a significant revenue decline, sending shares up 15.65% to $11.58, though the stock remains well below its 52-week high of $42.77.
The presentation outlined a challenging operating environment marked by weak demand across key regions, intensifying competition from generic alternatives to its flagship Rynaxypyr insecticide, and pricing pressure particularly acute in Latin America. However, management emphasized progress on strategic priorities including nearly $1 billion in planned asset sales and partnerships to reduce debt, cost improvements that helped preserve profitability, and growing momentum in new active ingredients.
Quarterly Performance Highlights
FMC’s second-quarter results reflected the dual pressures of declining sales and margin compression, tempered by better-than-expected cost management. As shown in the following financial summary, the company reported revenue of $867 million, down 17% from the prior year, with adjusted earnings per share of $0.26, a 62% decline year-over-year but above the $0.22 consensus estimate.
Revenue excluding India operations totaled $841 million, representing a 20% decline. The company posted a GAAP net loss of $187 million compared to net income of $67 million in the second quarter of 2025. Adjusted EBITDA fell 26% to $153 million, yielding an adjusted EBITDA margin of 18.1% excluding India, down 160 basis points from the prior year.
Key drivers of the quarter’s performance included volume declines in diamide products sold through partners and core legacy products, pricing pressure across all regions with the most pronounced reductions in Latin America, and lower branded Rynaxypyr sales excluding India. Partially offsetting these headwinds were higher sales in the growth portfolio driven by new active ingredients and Cyazypyr, as well as favorable raw material costs and supply chain improvements.
The company also announced it received registration approval for its Isoflex herbicide in the European Union, expanding the commercial reach of one of its newer active ingredients.
Regional Performance Analysis
The geographic breakdown of FMC’s second-quarter performance revealed weakness across all major markets, with Asia excluding India experiencing the steepest decline. The following regional revenue bridge illustrates how sales contracted from $1,051 million in the second quarter of 2025 to $841 million in the current quarter, excluding India operations.
North America revenue fell 22% to $249 million, driven by competitive market conditions and tight grower margins that led to lower volumes and trading down to lower-priced alternatives. The region did see solid growth in branded Rynaxypyr from new product introductions, but this was insufficient to offset broader volume declines.
Latin America posted revenue of $278 million, down 10% year-over-year or 16% excluding favorable foreign exchange impacts. The decline was primarily attributed to lower partner sales, though the company reported strong branded volume growth in Brazil including sales of its fluindapyr-based fungicide Onsuva. Pricing pressure was most severe in this region.
Asia excluding India saw revenue plunge 37% to $101 million, largely reflecting the comparison to the prior year when the India commercial business was still consolidated. Excluding this impact, the region showed solid growth in Australia and New Zealand.
EMEA revenue declined 18% to $214 million, negatively impacted by expected registration losses and extreme heat across the region. Growth of new active ingredients, particularly Isoflex, provided partial offset.
Across all regions, FMC experienced pricing pressure with declines in the mid to high-single digit range, reflecting both competitive dynamics and the company’s deliberate strategy to lower Rynaxypyr pricing to capture market share from older insecticides.
Profitability Drivers and Cost Management
Despite the revenue headwinds, FMC demonstrated improved cost discipline that helped adjusted EBITDA exceed the high end of company guidance. The following bridge chart illustrates the factors driving the $54 million year-over-year decline in adjusted EBITDA from $207 million to $153 million.
Volume, mix, and new product launches had a negative $47 million impact, as strong growth in new active ingredients was more than offset by lower overall volumes driven by reduced diamide partner sales and core legacy products. Pricing actions reduced EBITDA by $75 million, reflecting both competitive pressure and the company’s strategic decision to lower Rynaxypyr prices.
On the positive side, cost improvements contributed $62 million of favorability, primarily within gross margin through favorable raw materials and supply chain improvements. Foreign exchange provided a $6 million tailwind, mainly from the Brazilian real.
The adjusted EPS decline from $0.69 to $0.26 was driven by the lower EBITDA along with higher interest expense resulting from the company’s elevated debt levels. The following variance bridge shows that lower EBITDA accounted for $0.37 of the $0.43 per-share decline, with interest expense contributing another $0.07.
Strategic Initiatives and Debt Reduction
FMC’s presentation emphasized four operational priorities for 2026, centered on balance sheet improvement and portfolio repositioning. The company outlined a comprehensive plan to generate approximately $1 billion in proceeds for debt paydown through multiple initiatives.
The debt reduction strategy includes the sale of the India commercial business, active ingredient licensing agreements including an upfront payment from Corteva for rimisoxafen rights, property leaseback and other asset sales, and an equity investment from Tessenderlo Group. The company successfully completed a $1.2 billion secured bond offering in May, refinancing existing debt at more favorable terms.
To improve competitiveness of its core portfolio, FMC is lowering manufacturing costs of non-diamide core products and adjusting its Asia cost structure following the India commercial sale. The company expects restructuring spending of approximately $170 million in 2026.
The post-patent Rynaxypyr strategy involves continuing to reduce manufacturing costs, lowering prices to grow volume by capturing market share from older insecticides, and offering advanced mixtures and formulations to differentiate from generic solo offerings and address resistance challenges. According to the earnings call transcript, sales of differentiated Rynaxypyr formulations and mixtures grew more than 35% year-over-year.
FMC is also prioritizing growth of new active ingredients, with sales expected to reach $300 million to $400 million in 2026, representing more than 50% growth. Commercial licensing agreements are accelerating this growth, along with a continued strategy to increase direct-to-grower sales in Brazil.
Financial Outlook and Guidance
FMC provided updated guidance for the full year and remaining quarters of 2026, reflecting the challenging market conditions while positioning the year as a cyclical trough. The following outlook summary shows expected revenue of $3.50 billion to $3.70 billion, representing a 7% decline at the midpoint.
For the full year 2026, FMC expects adjusted EBITDA of $620 million to $680 million, down 23% year-over-year at the midpoint, and adjusted earnings per share of $1.19 to $1.49, representing a 55% decline. The guidance assumes volume in line with the prior year excluding India, 50%+ growth in new active ingredients, increased direct sales in Brazil, and higher sales in EMEA and Latin America. However, these positive factors are expected to be more than offset by mid to high-single digit price declines and a low-single digit foreign exchange headwind to EBITDA.
The third-quarter outlook calls for revenue of $840 million to $900 million, down 9% at the midpoint, with adjusted EBITDA of $120 million to $140 million and adjusted EPS of $0.05 to $0.13. Management indicated this would be the weakest quarter of the year, with North America distributors shifting orders to the fourth quarter to align purchases closer to application timing.
The fourth quarter is expected to show sequential improvement with revenue of $1.06 billion to $1.20 billion, up 4% year-over-year at the midpoint. Adjusted EBITDA guidance of $275 million to $315 million represents 5% growth, while adjusted EPS of $1.09 to $1.33 would be up 1% from the prior year.
Fourth-quarter revenue growth is expected to be driven by higher volume from increased direct sales to growers in Brazil, new active ingredients including the fluindapyr-based fungicide Adastrio in North America and Isoflex herbicide in Australia and Great Britain, and the timing shift of North America distributor orders from the third quarter. Management described 2026 as a trough year and indicated that work underway should position FMC to return to growth in 2027.
Cash Flow and Balance Sheet Improvements
Despite the earnings pressure, FMC demonstrated significant improvement in cash generation during the second quarter, supported by working capital management and the rimisoxafen licensing payment from Corteva. The following summary shows cash from operations of $363 million compared to $66 million in the prior-year quarter, an increase of $297 million.
Free cash flow surged to $357 million from $40 million in the second quarter of 2025, an increase of $318 million. The improvement included a $200 million upfront licensing payment for rimisoxafen and working capital release including contributions from India operations. Capital additions and other investing activities totaled just $6 million in the quarter.
For the full year 2026, FMC updated its free cash flow guidance to a range of $75 million to $225 million, up from previous expectations. The guidance now incorporates the $200 million rimisoxafen licensing payment and expected working capital contributions from India. The company expects capital additions and other investing activities of $50 million to $70 million for the year.
The cash flow bridge from adjusted EBITDA to free cash flow shows the impact of interest and tax payments, capital expenditures, restructuring and legacy costs, the licensing payment, and working capital changes. Management emphasized that debt reduction remains a top priority, with gross debt declining $250 million from the prior quarter to approximately $4.3 billion, while net debt fell $339 million to about $3.8 billion. However, at 5.1 times trailing 12-month EBITDA, leverage remains elevated.
The company provided detailed modeling assumptions for 2026, including interest expense of $275 million to $285 million, an adjusted tax rate of 16% to 18%, and depreciation and amortization of $160 million to $170 million.
FMC expects the loss of India contribution in 2026 to total approximately $90 million in revenue with no EBITDA impact, as the business was essentially breakeven. Full-year weighted average diluted shares outstanding are projected at 125.9 million.
The combination of asset sales, licensing partnerships, cost reductions, and working capital management is designed to strengthen FMC’s balance sheet and provide financial flexibility as the company works through the patent expiration cycle and positions for renewed growth. Management indicated on the earnings call that they believe "the worst is behind us" following the loss of Rynaxypyr patent protection and expect 2027 to mark the first year of growth as new products gain traction and the company benefits from a more competitive cost structure.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.